Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to Agios Pharmaceuticals Second Quarter twenty twenty six Conference Call. At this time, all participants are in a listen only mode. There will be a question and answer session at the end. Please be advised that this call is being recorded at AGIO's request. I would now like to turn the call over to Morgan Sanford, Head of Investor Relations at AGIO's. Thank you, operator. Good morning, everyone. Thank you for joining us to discuss Agios Pharmaceuticals' second quarter twenty twenty six financial results and business highlights. You can access the slides for today's call by going to the Investors section of our website, agios.com. Please note we'll be making certain forward looking statements today. Actual events and results could differ materially from those expressed or implied by any forward looking statements because of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. On the call with me today from Agios are Brian Goss, Chief Executive Officer Cecilia Jones, Chief Financial Officer Svetta Milanova, Chief Commercial Officer and Doctor. Sarah Huens, Chief Medical Officer and Head of Research and Development. Following prepared remarks, we will open the call for questions. With that, I am pleased to turn the call over to Brian. Thanks, Morgan. Good morning, everyone, and thank you for joining us. Before we review our second quarter results, I'd like to take a step back and highlight the strong position from which Agios is executing as we continue advancing toward our goal of building a multi billion dollar rare disease business. We are executing against multiple drivers of value creation, including the launch of ACVES...